Remimazolam comment watch save
BreastfeedingGeriatricPediatric

  • TRADE NAME: Byfavo (Acacia Pharma)
  • INDICATIONS: Induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less (intravenous administration).
  • SYNONYM: Remimazolam besylate
  • CLASS: Benzodiazepine
  • HALF-LIFE: 37–53 minutes (terminal elimination half-life from plasma)
  • FDA APPROVAL DATE: 07/02/2020
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known
  • PREGNANCY: Benzodiazepines cross the placenta and may produce respiratory depression and sedation in neonates.

Remimazolam should not be used in patients less than 18 years of age. Remimazolam may cause confusion and over-sedation in the elderly; elderly patients generally should be observed closely.

A case of intravenous line occlusion has been reported when using Acetated Ringer's solution and remimazolam (https://doi.org/10.1016/j.jclinane.2021.110190).

REMIMAZOLAM HAS BEEN ASSOCIATED WITH HYPOXIA, BRADYCARDIA, AND HYPOTENSION. CONCOMITANT USE OF BENZODIAZEPINES WITH OPIOID ANALGESICS MAY RESULT IN PROFOUND SEDATION, RESPIRATORY DEPRESSION, COMA, AND DEATH. THE SEDATIVE EFFECT OF INTRAVENOUS REMIMAZOLAM CAN BE ACCENTUATED BY CONCOMITANTLY ADMINISTERED CNS DEPRESSANT MEDICATIONS, INCLUDING OTHER BENZODIAZEPINES AND PROPOFOL.

See full prescribing information for complete boxed warning

Please login to view the rest of this drug profile.

Page last updated 08/21/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top